Mark de Jong, CTO of Canadian Isotope Innovations.

Mark de Jong

CTO

Prior to joining CII, Dr. de Jong was the Chief Medical Isotope Officer at Canadian Light Source Inc., heading up the CLS Medical Isotope Project to develop pilot production facility to produce Mo­99 via electron linear accelerators. Before that, he held various positions at Canadian Light Source Inc. including the Director of Accelerators, Director of Facility Operations and three times Interim Executive Director. Dr. de Jong was also the Project Leader for construction of the Canadian Light Source synchrotron radiation facility.

Prior to joining CLS, he worked at Chalk River Laboratories for over 18 years, first in the Accelerator Physics Branch working on development of technology for particle accelerators, and then in the Instrumentation and Control Systems Division where he managed a software group working on safety ­related and safety ­critical control systems for CANDU nuclear power reactors. Dr. de Jong received his Ph.D. in accelerator physics from the University of Manitoba.